China - HealthQuill

Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing average blood sugar levels by up to 2.16% in diabetic patients and trimmed weight by almost 10%, according to a statement.

Novo, United’s trial drug cuts sugar levels by 2.16%, weight loss of 9.8%

HQ Team March 25, 2026: Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing.

by HealthQuill
March 25, 2026
0 Comments

The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.

Drugs Health Pharma

AstraZeneca, Amgen’s drug for nasal inflammation gets EU nod

The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.

by HealthQuill
October 22, 2025
0 Comments

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development of its immuno-oncology and antibody-drug conjugate cancer therapies.

Drugs Health Pharma

China’s Innovent, Japan’s Takeda in $11.4 billion deal for cancer therapies

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.

by HealthQuill
October 22, 2025
0 Comments

Merck and Co. will invest up to $70 billion to expand its domestic manufacturing in the US after President Donald Trump urged pharmaceutical companies to set up their bases within the country and reduce reliance on imports of drugs.

Drugs Health Pharma

Merck to spend $70 billion to expand domestic manufacturing in US

Merck and Co. will invest up to $70 billion to expand its domestic manufacturing in the US after President Donald Trump urged pharmaceutical.

by HealthQuill
October 21, 2025
0 Comments

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.

Drugs Health Pharma

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

by HealthQuill
October 9, 2025
0 Comments

https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis

Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

by HealthQuill
September 4, 2025
0 Comments

Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.

Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

by HealthQuill
July 28, 2025
0 Comments

The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on the table as more information is needed to fully evaluate both, according to the World Health Organization.

Drugs Health Pharma

WHO says more information needed to track SARS-CoV-2 origins

HQ Team June 30, 2025: The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on.